Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944 · see citing works

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

Chobanian, A. V. (2003) · JAMA · doi:10.1001/jama.289.19.2560 · Cited by 25,386 · see citing works

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

(2002) · Circulation · doi:10.1161/circ.106.25.3143 · Cited by 14,092 · see citing works

Diagnosis and Classification of Diabetes Mellitus

American Diabetes Association (2010) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 14,019 · see citing works

Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)

Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198 · see citing works

Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902 · see citing works

The metabolic syndrome

Eckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,283 · see citing works

The metabolic syndrome

Eckel, R. H., Grundy, S. M., & Zimmet, P. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,565 · see citing works

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

Smith, S. C., Allen, J. K., Blair, S. N., Bonow, R. O., Brass, L. M., Fonarow, G. C., Grundy, S. M., Hiratzka, L. F., Jones, D. W., Krumholz, H. M., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.174516 · Cited by 2,088 · see citing works

Hyperinsulinemia as an independent risk factor for ischemic heart disease

Després, J.-P., Lamarche, B., Mauriège, P., Cantin, B., Dagenais, G. R., Moorjani, S., & Lupien, P.-J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341504 · Cited by 1,699 · see citing works

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09408-4 · Cited by 1,686 · see citing works

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455 · see citing works

Standards of Medical Care in Diabetes—2008

Dora, J. M., Kramer, C. K., & Canani, L. H. S. (2008) · Diabetes Care · doi:10.2337/dc08-0109 · Cited by 1,414 · see citing works

Standards of Medical Care in Diabetes—2008

American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s012 · Cited by 1,377 · see citing works

The Metabolic Syndrome

Grundy, S. M. (2010) · Springer eBooks · doi:10.1007/978-1-4419-5839-6_1 · Cited by 1,225 · see citing works

Diagnosis and Classification of Diabetes Mellitus

American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s055 · Cited by 1,062 · see citing works

Duration of Androgen Suppression in the Treatment of Prostate Cancer

Bolla, M., de Reijke, T. M., van Tienhoven, G., van den Bergh, A. C. M., Oddens, J. R., Poortmans, P. M., Gez, E., Kil, P. J. M., Akdaş, A., Soete, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810095 · Cited by 970 · see citing works

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85–31

Pilepich, M. V., Winter, K. A., Lawton, C. A., Krisch, R. E., Wolkov, H. B., Movsas, B., Hug, E. B., Asbell, S. O., & Grignon, D. J. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.08.047 · Cited by 912 · see citing works

Changes in body composition during androgen deprivation therapy for prostate cancer

Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8299 · Cited by 697 · see citing works

Androgen Suppression and Radiation vs Radiation Alone for Prostate Cancer

D'Amico, A. V., Chen, M., Renshaw, A. A., Loffredo, M. J., & Kantoff, P. W. (2008) · JAMA · doi:10.1001/jama.299.3.289 · Cited by 692 · see citing works

Ten-Year Follow-Up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer

Horwitz, E. M., Bae, K., Hanks, G. E., Porter, A. T., Grignon, D. J., Brereton, H. D., Venkatesan, V., Lawton, C. A., Rosenthal, S. A., Sandler, H. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9021 · Cited by 687 · see citing works

Short-Term Neoadjuvant Androgen Deprivation Therapy and External-Beam Radiotherapy for Locally Advanced Prostate Cancer: Long-Term Results of RTOG 8610

Roach, M., Bae, K., Speight, J. L., Wolkov, H. B., Rubin, P., Lee, R. J., Lawton, C. A., Valicenti, R. K., Grignon, D. J., & Pilepich, M. V. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9881 · Cited by 649 · see citing works

Metabolic Syndrome in Men With Prostate Cancer Undergoing Long-Term Androgen-Deprivation Therapy

Braga‐Basaria, M., Dobs, A. S., Muller, D. C., Carducci, M. A., John, M., Egan, J. M., & Basaria, S. S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9741 · Cited by 582 · see citing works

Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer

Saigal, C. S., Gore, J. L., Krupski, T. L., Hanley, J., Schonlau, M., & Litwin, M. S. (2007) · Cancer · doi:10.1002/cncr.22933 · Cited by 542 · see citing works

Cigarette Smoking, Cardiovascular Disease, and Stroke: A Statement for Healthcare Professionals From the American Heart Association

Ockene, I. S., & Miller, N. H. (1997) · Circulation · doi:10.1161/01.cir.96.9.3243 · Cited by 541 · see citing works

Androgen Deprivation Therapy for Localized Prostate Cancer and the Risk of Cardiovascular Mortality

Tsai, H. K., D'Amico, A. V., Sadetsky, N., Chen, M., & Carroll, P. R. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm168 · Cited by 520 · see citing works

Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions

D'Amico, A. V., Denham, J. W., Crook, J., Chen, M.-H., Goldhaber, S. Z., Lamb, D. S., Joseph, D., Tai, K.-H., Malone, S., Ludgate, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.3369 · Cited by 501 · see citing works

Insulin sensitivity during combined androgen blockade for prostate cancer

Smith, M. R., Lee, H., & Nathan, D. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2507 · Cited by 493 · see citing works

The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer

Smith, J. C., Bennett, S., Evans, L. M., Kynaston, H. G., Parmar, M., Mason, M. D., Cockcroft, J. R., Scanlon, M. F., & Davies, J. S. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7851 · Cited by 458 · see citing works

Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial

Denham, J. W., Steigler, A., Lamb, D. S., Joseph, D. J., Mameghan, H., Turner, S., Matthews, J., Franklin, I., Atkinson, C. H., North, J., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70348-x · Cited by 374 · see citing works

Hyperinsulinemia Predicts Coronary Heart Disease Risk in Healthy Middle-aged Men

Pyörälä, M., Miettinen, H., Laakso, M., & Pyörälà, K. (1998) · Circulation · doi:10.1161/01.cir.98.5.398 · Cited by 346 · see citing works

Impact of Androgen Deprivation Therapy on Cardiovascular Disease and Diabetes

Alibhai, S. M. H., Duong-Hua, M., Sutradhar, R., Fleshner, N. E., Warde, P. R., Cheung, A. M., & Paszat, L. F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0923 · Cited by 334 · see citing works

Immediate or Deferred Androgen Deprivation for Patients With Prostate Cancer Not Suitable for Local Treatment With Curative Intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891

Studer, U. E., Whelan, P., Albrecht, W., Casselman, J., de Reijke, T. M., HAURI, D., Loidl, W. C., Isorna, S., Sundaram, S. K., Debois, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7423 · Cited by 327 · see citing works

Changes in Bone Mineral Density, Lean Body Mass and Fat Content as Measured by Dual Energy X-Ray Absorptiometry in Patients With Prostate Cancer Without Apparent Bone Metastases Given Androgen Deprivation Therapy

Berruti, A., Dogliotti, L., Terrone, C., CERUTTI, S., Isaia, G., Tarabuzzi, R., Reimondo, G., Mari, M., Ardissone, P., LUCA, S. D., et al. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)64985-3 · Cited by 315 · see citing works

Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia

Dockery, F., Bulpitt, C. J., AGARWAL, S., Donaldson, M., & Rajkumar, C. (2003) · Clinical Science · doi:10.1042/cs20020209 · Cited by 294 · see citing works

Hormonal Therapy Use for Prostate Cancer and Mortality in Men With Coronary Artery Disease–Induced Congestive Heart Failure or Myocardial Infarction

Nanda, A. (2009) · JAMA · doi:10.1001/jama.2009.1137 · Cited by 279 · see citing works

Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31

Efstathiou, J. A., Bae, K., Shipley, W. U., Hanks, G. E., Pilepich, M. V., Sandler, H. M., & Smith, M. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3752 · Cited by 260 · see citing works

Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer

Smith, M. R. (2004) · Urology · doi:10.1016/j.urology.2003.10.063 · Cited by 259 · see citing works

Metabolic changes during gonadotropin‐releasing hormone agonist therapy for prostate cancer

Smith, M. R., Lee, H., McGovern, F. J., Fallon, M. A., Goode, M., Zietman, A. L., & Finkelstein, J. S. (2008) · Cancer · doi:10.1002/cncr.23440 · Cited by 207 · see citing works

Cardiovascular Mortality and Duration of Androgen Deprivation for Locally Advanced Prostate Cancer: Analysis of RTOG 92-02

Efstathiou, J. A., Bae, K., Shipley, W. U., Hanks, G. E., Pilepich, M. V., Sandler, H. M., & Smith, M. R. (2008) · European Urology · doi:10.1016/j.eururo.2008.01.021 · Cited by 199 · see citing works

Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial

Kibel, A. S. (2008) · Yearbook of Urology · doi:10.1016/s0084-4071(08)79094-8 · Cited by 178 · see citing works

Changes in bone mineral density and body composition during initial and long‐term gonadotropin‐releasing hormone agonist treatment for prostate carcinoma

Lee, H., McGovern, K., Finkelstein, J. S., & Smith, M. R. (2005) · Cancer · doi:10.1002/cncr.21381 · Cited by 148 · see citing works

Adipocytokines, Obesity, and Insulin Resistance During Combined Androgen Blockade for Prostate Cancer

Smith, M. R., Lee, H., Fallon, M. A., & Nathan, D. M. (2008) · Urology · doi:10.1016/j.urology.2007.08.035 · Cited by 121 · see citing works

Endocrine treatment of prostate cancer

Tammela, T. L. J. (2004) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2004.10.005 · Cited by 113 · see citing works

Effects of the Luteinizing Hormone-Releasing Hormone Agonist Leuprolide on Lipoproteins, Fibrinogen and Plasminogen Activator Inhibitor in Patients with Benign Prostatic Hyperplasia

Eri, L. M., Urdal, P., & Bechensteen, A. G. (1995) · The Journal of Urology · doi:10.1016/s0022-5347(01)67239-2 · Cited by 100 · see citing works

Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer.

Tayek, J., Heber, D., Byerley, L., Steiner, B., Rajfer, J., & Swerdloff, R. S. (1990) · Metabolism: Clinical and Experimental · doi:10.1016/0026-0495(90)90190-n · Cited by 78 · see citing works

Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer

D'Amico, A. V., Chen, M., Renshaw, A. A., Loffredo, M. J., & Kantoff, P. W. (2008) · Cancer · doi:10.1002/cncr.23970 · Cited by 39 · see citing works

Rising PSA in nonmetastatic prostate cancer.

Moul, J. W., Bañez, L. L., & Freedland, S. J. (2007) · PubMed · Cited by 36 · see citing works

Survival of colorectal cancer cell lines treated with paclitaxel, radiation, and 5-FU: Effect of TP53 or hMLH1 deficiency

Kennedy, A. S., Harrison, G. H., Mansfield, C. M., Zhou, X. J., Xu, J., & Balcer‐Kubiczek, E. K. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000820)90:4 · Cited by 29 · see citing works

Nonhormonal mechanism of sexual inadequacy in patients with varicocele

Nahoum, C. R. D., & Freire, F. (1985) · Urology · doi:10.1016/0090-4295(85)90563-1 · Cited by 22 · see citing works

Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline

Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945 · see citing works

Testosterone and obesity

Kelly, D. M., & Jones, T. H. (2015) · Obesity Reviews · doi:10.1111/obr.12282 · Cited by 487 · see citing works

Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes

Muraleedharan, V., Marsh, H., Kapoor, D., Channer, K. S., & Jones, T. H. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0321 · Cited by 389 · see citing works

Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review

Gardner, J. R., Livingston, P. M., & Fraser, S. F. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.5523 · Cited by 243 · see citing works

Onset of effects of testosterone treatment and time span until maximum effects are achieved

Saad, F., Aversa, A., Isidori, A. M., Zafalon, L., Zitzmann, M., & Gooren, L. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0221 · Cited by 232 · see citing works

Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review

Saad, F., Aversa, A., M. Isidori, A., & J. Gooren, L. (2012) · Current Diabetes Reviews · doi:10.2174/157339912799424573 · Cited by 148 · see citing works

Effectiveness of Primary Androgen-Deprivation Therapy for Clinically Localized Prostate Cancer

Potosky, A. L., Haque, R., Cassidy-Bushrow, A. E., Ulcickas Yood, M., Jiang, M., Tsai, H.-T., Luta, G., Keating, N. L., Smith, M. R., & Van Den Eeden, S. K. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.5782 · Cited by 75 · see citing works

Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy

Storer, T. W., Miciek, R., & Travison, T. G. (2012) · Asian Journal of Andrology · doi:10.1038/aja.2011.104 · Cited by 70 · see citing works

Management of side effects of androgen deprivation therapy

Grossmann, M., & Zajac, J. D. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2011.05.004 · Cited by 69 · see citing works

Complications of androgen deprivation therapy in prostate cancer / a review

Rolim, N., Lopes, F. I., Rodrigues, T., et al. (2017) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)

Androgen deprivation therapy for prostate cancer

Das, M. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30670-8 · Cited by 4 · see citing works

Uncovering the Metabolic Complications of Androgen Deprivation Therapy in Patients with Prostate Cancer—Where Do We Take it Next?

Pinthus, J. H. (2015) · The Journal of Urology · doi:10.1016/j.juro.2015.03.070 · Cited by 2 · see citing works

Metabolic Complications and Increased Cardiovascular Risks as a Result of Androgen Deprivation Therapy in Men with Prostate Cancer

Shastri, B. R., & Yaturu, S. (2011) · Prostate Cancer · doi:10.1155/2011/391576 · Cited by 10 · see citing works

How to Treat Prostate Cancer With Androgen Deprivation and Minimize Cardiovascular Risk

Narayan, V., Ross, A. E., Parikh, R. B., Nohria, A., & Morgans, A. K. (2021) · JACC CardioOncology · doi:10.1016/j.jaccao.2021.09.014 · Cited by 43 · see citing works